PSIL AdvisorShares Psychedelics ETF Loading...

Loading chart...
Top Calls
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
Loading...
0 selected
All Content✓
Source feeds
Buzzberg's Top 50 ✓
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
17:45
Apr 22
Christian Angermayer Founder, Cryptology Asset Group CNBC
Psychedelics have high clinical success rates.
Psychedelics are becoming medically accepted again with clinical trials showing up to 80% responder rates for treatment-resistant depression, addiction, and anxiety disorders. The recent executive order from President Trump accelerates federal funding for research, and the drugs are used in a clinical setting with a therapist, ensuring safety and efficacy. The sector has strong growth potential and companies have patent protection and intellectual property.
PSIL 1ST
HIGH
18:57
Apr 20
Eric Balchunas Senior ETF Analyst, Bloomberg Intelligence Bloomberg Markets
PSIL ETF responsive to regulatory catalysts.
The PSIL (psychedelics) ETF, which had been depressed, saw a significant price pop and high trading volume after positive regulatory news (an executive order expediting research), suggesting that any good news can lead to substantial upside in such beaten-down, headline-sensitive thematic ETFs.
PSIL
MED

About PSIL Analyst Coverage

Buzzberg tracks PSIL (AdvisorShares Psychedelics ETF) across 2 sources. 1 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (50%). 2 total trade ideas tracked.